Format

Send to

Choose Destination
Cytokine Growth Factor Rev. 2015 Feb;26(1):7-13. doi: 10.1016/j.cytogfr.2014.09.003. Epub 2014 Oct 2.

Negative regulation of RelA phosphorylation: emerging players and their roles in cancer.

Author information

1
Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA; Department of Medicine, University of California at San Francisco, San Francisco, CA, USA.
2
Division of Otolaryngology, Department of Surgery, Yale University, New Haven, CT, USA; Department of Pathology, Yale University, New Haven, CT, USA; Yale Cancer Center, New Haven, CT, USA. Electronic address: christine.purcell@yale.edu.

Abstract

NF-κB signaling contributes to human disease processes, notably inflammatory diseases and cancer. Many advances have been made in understanding mechanisms responsible for abnormal NF-κB activation with RelA post-translational modification, particularly phosphorylation, proven to be critical for RelA function. While the majority of studies have focused on identifying kinases responsible for NF-κB phosphorylation and pathway activation, recently progress has also been made in understanding the negative regulators important for restraining RelA activity. Here we summarize negative regulators of RelA phosphorylation, their targeting sites in RelA and biological functions through negative regulation of RelA activation. Finally, we emphasize the tumor suppressor-like roles that these negative regulators can assume in human cancers.

KEYWORDS:

LZAP; NF-κB; PPM1A; Phosphatase; Tumor suppressor

PMID:
25438737
DOI:
10.1016/j.cytogfr.2014.09.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center